The National Pharmaceutical Pricing Authority (NPPA) on March 25, 2026, under the provisions of the Drugs (Prices Control) Order, 2013 (DPCO, 2013), has fixed revised ceiling prices for specified scheduled formulations, superseding earlier price orders. These prices are exclusive of GST and will be effective from April 1, 2026, incorporating a WPI increase of 0.64956% for 2025 over 2024.
Manufacturers are required to revise prices downward if existing MRPs exceed the notified ceiling prices, while those with lower MRPs may revise prices upward within the permitted WPI adjustment. For formulations or pack sizes not covered, prior approval from NPPA must be obtained. GST can be added only if actually payable.
The order also prescribes strict compliance and reporting requirements, including submission of price revisions (Form-II), price lists (Form-V), and quarterly returns (Form-III). Non-compliance, overcharging, or failure to report may attract recovery of overcharged amounts with interest under DPCO, 2013 and the Essential Commodities Act, 1955.
[Notification No. S.O. 1581(E)]
